External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Sun Pharmaceutical Industries / Equity Bottom-Up

<ul><li>Sun Pharma’s (SUNP) formulation manufacturing facility at Halol (Gujarat, India) had an inspection from the USFDA for current Good Manufacturing Practices (cGMP)</li><li>The inspection was conducted between 2–13 June 2025 and concluded with eight Form 483 observations</li><li>The observations are critical in nature as well as repeated from its previous USFDA inspection during May ’22</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Sun Pharma’s (SUNP) formulation manufacturing facility at Halol (Gujarat, India) had an inspection from the USFDA for current Good Manufacturing Practices (cGMP)The inspection was conducted between 2–13 June 2025 and concluded with eight Form 483 observationsThe observations are critical in nature as well as repeated from its previous USFDA inspection during May ’22Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sun Pharmaceutical Industries: Halol Observations Were Critical, No Relief to Plant.